09 Mar2015
New CEO in Town!
Golimumab Benefits Hold Up Over Time in RA
-Negligible radiographic progression seen through 2 years of treatment.
Clinical responses to intravenous golimumab (Simponi Aria) among patients with rheumatoid arthritis persisted through 2 years of treatment, a study known as GO-FURTHER found.
Among 486 patients who completed 2 years of treatment with intravenous golimumab plus methotrexate, a 20% improvement according to the criteria of the American College of Rheumatology (ACR20) was seen in 68.1%, according to Clifton O. Bingham III, MD, of Johns Hopkins University, and colleagues.
